Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125978471 | 12597847 | 1 | I | 2014 | 20160303 | 20160726 | 20160726 | PER | US-MYLANLABS-2016M1011589 | MYLAN | 0.00 | F | Y | 58.97000 | KG | 20160726 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125978471 | 12597847 | 1 | PS | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 10 MG, QD | 91226 | 10 | MG | TABLET | QD | ||||||
| 125978471 | 12597847 | 2 | SS | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | 10 MG, QD | 0 | 10 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125978471 | 12597847 | 1 | Blood cholesterol |
| 125978471 | 12597847 | 2 | Blood pressure management |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125978471 | 12597847 | Blood glucose increased | |
| 125978471 | 12597847 | Haematuria | |
| 125978471 | 12597847 | Muscle spasms |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125978471 | 12597847 | 1 | 201408 | 0 | ||
| 125978471 | 12597847 | 2 | 201408 | 0 |